A new study provides the first detailed look at Kyprolis when it is used in multiple myeloma patients with kidney damage.

The focus of the study is on determining how Kyprolis (car­filz­o­mib) is processed in the bodies of myeloma patients and, in particular, if the drug is processed differently depending on how much kidney damage a patient has.

In addi­tion, the study in­ves­ti­gates whether kidney damage affects how often patients experience side effects when treated with Kyprolis.

Based on the …

As many of you may already know, February is 'Heart Month,' so I decided to write a bit in my column about blood donations, since that seems to be related to the theme.

The heart is the pump for our blood, and myeloma is one of the three main types of blood cancer, the other two being leukemia and lymphoma.

Back in my pre-myeloma days, I was an occasional blood donor.  Although I only donated about 20 times overall, …

On Friday, the U.S. Food and Drug Administration (FDA) approved Pomalyst (pomalidomide) for the treatment of multiple myeloma patients who have received at least two prior therapies (see related Beacon news).

In this article, The Beacon addresses important questions multiple myeloma patients have been asking about the FDA decision.  The article is organized similarly to one the Beacon published about Kyprolis (carfilzomib) after it …

In the column I wrote two months ago, I relayed how I was doing 100 days after my allogeneic (donor) stem cell transplant.

I struck a pretty optimistic note.  I felt that the transplant itself had gone really well and that the big question that was still out there was whether it would work to control my multiple myeloma for a meaningful amount of time.

Unfortunately, I may have gotten my answer sooner than I expected.

I was really …

The Myeloma Beacon is pleased to announce the introduction of Spanish-language translations of select articles at the Beacon website.

“I am very pleased that we will be able to offer these translations to our Spanish-speaking readers.  The Beacon community is growing rapidly, and more and more of our readers are from areas of the world where Spanish is the primary language,” said Maike Haehle, associate publisher of The Myeloma Beacon.

Articles available in Spanish will be marked with a …

The United States Food and Drug Administration (FDA) has approved pomalidomide, which will be marketed under the brand name Pomalyst, for the treatment of relapsed and refractory multiple myeloma.

Specifically, Pomalyst has been approved for use in patients with multiple myeloma who have received at least two prior therapies including Rev­limid (lenalido­mide) and Velcade (bortezomib) and have demon­strat­ed disease progression on or within 60 days of completion of the last therapy.

Celgene (NASDAQ:CELG), the company that …

The "what will the FDA decide about pomalidomide" waiting game is reaching its final hours, and the drama is peaking.

Celgene (CELG:NASDAQ), the company that has been developing poma­lido­mide, asked the U.S. Food and Drug Administration (FDA) last April to approve the drug for the treatment of relapsed and refractory myeloma.

Based on the date the company filed its new drug application with the FDA, the regulator is required to make a decision on the application by this …